ICMR & Panacea Biotec complete enrollment for India's first indigenous dengue vaccine phase 3 study
DengiAll will be the first indigenous single-shot dengue vaccine in India and is expected to enter the markets by 2027
DengiAll will be the first indigenous single-shot dengue vaccine in India and is expected to enter the markets by 2027
Gland Pharma receives approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
The work will leverage ProBioGen’s CHO.RiGHT expression platform, powered by its proprietary DirectedLuck transposase technology, alongside PsiBot smart automation
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma (NHL) in adults, represents 40% of all cases worldwide
Heart failure affects an estimated 64.3 million people worldwide
WuXi Biologics has integrated sustainability principles throughout its supplier lifecycle management
Kelun-Biotech and Crescent Biopharma forged a collaboration covering SKB105/CR-003 and SKB118, a PD-1 x VEGF bispecific antibody also known as CR-001
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
The company previously completed a $150 million venture investment, acquisition, and recapitalization
Valneva said regaining full rights to the vaccine will allow the company to “assume direct control over its supply chain and commercialization for endemic high-risk countries
Subscribe To Our Newsletter & Stay Updated